undamentalytics Newsletter

Merck & Co. balance sheet

At the end of fiscal 2025, Merck & Co. had total assets of $136.87bn and shareholders' equity of $52.61bn. It held $14.56bn in cash against $49.34bn of debt: net debt of $34.77bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Merck & Co.: balance sheet, annual
Fiscal year2007Dec 20072008Dec 20082009Dec 20092010Dec 20102016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5.34.49.310.96.56.18.09.78.18.112.76.813.214.66.8
Receivables—2.86.67.37.06.97.16.86.89.29.510.310.311.812.6
Inventory—2.18.05.94.95.15.46.05.66.05.96.46.16.76.2
Total current assets—19.128.429.130.624.825.927.527.830.335.732.238.843.536.7
Goodwill—1.412.012.418.218.318.318.118.921.321.221.221.721.621.6
Total assets—47.2112.3105.895.487.982.684.491.6105.7109.2106.7117.1136.9129.8
Accounts payable—0.62.22.32.83.13.33.74.34.64.33.94.14.43.8
Total current liabilities—14.315.615.617.218.622.222.227.323.924.225.728.428.327.7
Short-term debt—2.31.42.40.63.15.33.66.42.41.91.42.62.62.8
Long-term debt—3.916.115.524.321.419.822.725.430.728.733.734.546.851.1
Total debt0.06.217.517.924.824.425.126.331.833.130.735.137.149.353.9
Shareholders' equity20.618.859.154.440.134.326.725.925.338.246.037.646.352.641.9
Net debt (negative = net cash)−5.31.98.27.018.318.317.116.723.825.018.028.323.934.847.1

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MRK vs PFEAZN vs MRKLLY vs MRK

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Merck & Co.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Merck & Co.